SCHEMBL25898917

SCHEMBL25898917

CC(C)(C)C(=O)Nc1ccc2cc(C(C)(C)C)ccc2n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.52
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
ADORA1 P30542 2/20 0.43
MCHR1 Q99705 1/20 0.41
NPC1 O15118 5/20 0.41
RAB9A P51151 5/20 0.41
MTTP P55157 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
BRAF P15056 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.39
TRPV1 Q8NER1 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
TP53 P04637 1/20 0.39
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12755257 0.88 MAPT (0.52) MAPTMEN1KMT2AMCHR1NPC1
SCHEMBL21864960 0.85 TYR (0.45) MAPTMEN1KMT2AADORA1NPC1
SCHEMBL25494328 0.84 MAPT (0.55) MAPTMEN1KMT2AMCHR1NPC1
SCHEMBL25494341 0.84 MAPT (0.49) MAPTMEN1KMT2AADORA1MCHR1
SCHEMBL20047089 0.84 SORT1 (0.46) MAPTADORA1NPC1RAB9AL3MBTL1
SCHEMBL21864961 0.81 MEN1 (0.50) MAPTMEN1KMT2ANPC1RAB9A
SCHEMBL22521523 0.80 NCF1 (0.50) MAPTMEN1KMT2AMCHR1MTTP
SCHEMBL5676796 0.80 NPC1 (0.59) MAPTKMT2AADORA1NPC1RAB9A
SCHEMBL25449359 0.78 ADORA1 (0.43) MAPTMEN1KMT2AADORA1NPC1
SCHEMBL25494333 0.78 MAPT (0.43) MAPTMEN1KMT2AMCHR1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230226214-A1 BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION LYCIA THERAPEUTICS, INC. 2023-07-20 US disclosed
US-20230226214-A1 BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION LYCIA THERAPEUTICS, INC. 2023-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226214-A1 BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION HAVCR2, FCGR3B, FCGR2A MAPT 3491/4885MEN1 1824/4885KMT2A 3875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.